PKD1 x SHANK3

This is a Phase 1, First-in-Human study to evaluate the safety and tolerability of PYC-003 in healthy adult participants and adult participants with confirmed PKD1 mutation-associated ADPKD. In Phase A of this study, healthy adult participants will either receive a single dose of PYC-003 or a placebo. Phase B, healthy adult participant will not receive any intervention and will serve as a baseline. Phase C, adult participants with confirmed PKD1 mutation-associated ADPKD will receive a dose of PYC-003.